Voyager Therapeutics (VYGR) Total Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $56.4 million for Q3 2024.

• In Q3 2024, Total Non-Current Liabilities fell 43.36% year-over-year to $56.4 million; the TTM figure through Sep 2024 stood at $56.4 million (down 43.36% YoY), while the FY2023 annual figure was $96.9 million, up 22.55% from the prior year.
• Total Non-Current Liabilities came in at $56.4 million for Q3 2024 at Voyager Therapeutics, down from $59.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $211.8 million in Q1 2020 to a low of $56.3 million in Q3 2021.
• Average Total Non-Current Liabilities over 5 years is $91.5 million, with a median of $80.6 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities plunged 72.44% in 2021 and jumped 88.68% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $62.9 million in 2020, then retreated by 5.83% to $59.2 million in 2021, then surged by 33.54% to $79.0 million in 2022, then rose by 22.55% to $96.9 million in 2023, then tumbled by 41.81% to $56.4 million in 2024.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $56.4 million in Q3 2024, $59.6 million in Q2 2024, and $85.7 million in Q1 2024.